Entera Bio’s (ENTX) Buy Rating Reiterated at HC Wainwright

Entera Bio (NASDAQ:ENTX)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They presently have a $10.00 target price on the stock. HC Wainwright’s price target suggests a potential upside of 481.40% from the company’s current price.

Entera Bio Price Performance

NASDAQ ENTX opened at $1.72 on Monday. Entera Bio has a fifty-two week low of $0.52 and a fifty-two week high of $3.35. The business has a fifty day moving average price of $1.87 and a two-hundred day moving average price of $1.92. The stock has a market capitalization of $61.54 million, a PE ratio of -6.62 and a beta of 1.58.

Entera Bio (NASDAQ:ENTX) last released its quarterly earnings data on Friday, November 8th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.03). The company had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.04 million. As a group, sell-side analysts expect that Entera Bio will post -0.23 earnings per share for the current year.

Hedge Funds Weigh In On Entera Bio

An institutional investor recently bought a new position in Entera Bio stock. Virtu Financial LLC purchased a new position in shares of Entera Bio Ltd. (NASDAQ:ENTX) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 22,040 shares of the company’s stock, valued at approximately $37,000. 14.11% of the stock is owned by hedge funds and other institutional investors.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.